Drugmaker Beijing Danxu Biopharmaceutical has garnered nearly 300 million yuan ($47 million) in a Series B financing round led by MSA Capital.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
